GSK650394

For research use only. Not for use in humans.

製品コードS7209

GSK650394化学構造

分子量(MW):382.45

GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.

サイズ 価格(税別) 在庫  
JPY 18100 あり
JPY 67900 あり
JPY 164100 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

カスタマーフィードバック(2)

  • BV-2 cells were incubated in the absence or presence of gsk650394 (1 μM) for 30 min, followed by LPS (500 ng/ml) administration for 30 min, and then fixed. NF-κB p65 protein was visualized by indirect immunofluorescence staining using an antibody for NF-κB p65. For nuclear staining, the cells were stained with DAPI. Bar = 20 μm.

    Biochem Biophys Res Commun, 2016, 478(1):53-59. GSK650394 purchased from Selleck.

    GSK650394 treatment reduces steady state levels of BoHV-1 proteins. Cells were grown prior to infection. Three hours prior to infection 25 nM of GSK650394 was added to the designated cultures. CRIB cells were infected withBoHV-1 (moi=2) and then stripped FBS added. At the designated times after infection (hours), whole cell lysate (50 ug protein) was prepared and Western Blots performedusing the designated antibodies directed against a viral protein. Arrows denote the position of bICP0 (97 kD), bICP4 (178 kD), bICP22 (45 kD), VP16 (65 kD), and the bracketdenotes various gE forms. Tubulin was used as a loading control. The lane marked M are molecular weight markers: numbers to left are the approximate size of the respectivebands. These results are representative of 4 independent experiments. The relative levels of the respective BoHV-1 proteins were estimated by comparing the intensity ofthe bands to tubulin using a BioRad ChemiDoc MP and PMI System. The value of the respective viral protein that was first detected after infection was set at 10 and the othervalues normalized to this value. ND refers to those lanes in which the viral protein was not detected. These results are representative of three independent experiments.

    Virus Res, 2016, 222:106-112.. GSK650394 purchased from Selleck.

製品安全説明書

Serine/threonin kinase阻害剤の選択性比較

生物活性

製品説明 GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.
ターゲット
SGK1 [1]
(Cell-free assay)
SGK2 [1]
(Cell-free assay)
62 nM 103 nM
体外試験

GSK650394 inhibits SGK1-mediated epithelial transport with an IC50 of 0.6 μM in the SCC assay. In LNCaP cells, GSK650394 inhibits the androgen-mediated enhancement of Nedd4-2 phosphorylation and androgen-mediated cell growth. [2] GSK650394 counteracts the Cortisol-induced decrease in neurogenesis, changes in Hedgehog signaling, and GR nuclear translocation. [2] GSK 650394 inhibits replication of influenza virus by impairing the export of influenza vRNPs into the cytoplasm of A549 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human M-1 cells MXfGeY5kfGmxbjDhd5NigQ>? NIPaO2dKdmirYnn0bY9vKG:oIGPHT|EudWWmaXH0[YQh\XCrdHjlcIlidCC|b3TpeY0h[2ijbn7lcEBi[3Srdnn0fUBqdiCqdX3hckBONTFiY3XscJMh[XO|ZYPz[YQh[XNic3jvdpQh[2m{Y4XpeEBkfXK{ZX70JIJ6KHeqb3zlJINmdGxiZXzlZ5Rzd3CqeYPpc4xw\2mlYXygeJJidnOncHn0bIVtcWGuIHX4dIVzcW2nboSsJGlEPTB;MD61PEDPxE1? NXzq[2poOTl2OUe3OFU>
human MV-4-11 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2q4bWlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ2OTFOwG0> MX\TRW5ITVJ?
human Daoy cell NHP2T5hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkWxOVMzKM7:TR?= MoO1V2FPT0WU
human BFTC-905 cell NH3pPHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1W0XWlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd6NEW1JO69VQ>? NFz3NHJUSU6JRWK=
human KM12 cell M1nIe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVy2U3htUW6qaXLpeIlwdiCxZjDoeY1idiCNTUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PTB4OTFOwG0> MX7TRW5ITVJ?
human GDM-1 cell MnfDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWrBR2oxUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDd7M{eg{txO M3\oNHNCVkeHUh?=
human RT-112 cell NXrINWc6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzhXmE5UW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjB{N{iyJO69VQ>? MWjTRW5ITVJ?
human MONO-MAC-6 cell M13vTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVPoRnFpUW6qaXLpeIlwdiCxZjDoeY1idiCPT17PMW1CSy14IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6xPFA6PyEQvF2= NFLRbnFUSU6JRWK=
human HUTU-80 cell MmTQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{Xwc2lvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzBzN{Kg{txO M{fsfnNCVkeHUh?=
human HGC-27 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjvTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMxQDJzIN88US=> M{frV3NCVkeHUh?=
human LCLC-97TM1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmC1TY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|Nke2PEDPxE1? MkHjV2FPT0WU
human LXF-289 cell MmjES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQxOTV{IN88US=> NEfveZlUSU6JRWK=
human HLE cell M3L5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX\nOZhVUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQzPjh|IN88US=> NEe1XWhUSU6JRWK=
human RKO cell NYnyTnR6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWDJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNUe4Olkh|ryP NGiwenZUSU6JRWK=
human SNG-M cell NXvHbnRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkH1TY5pcWKrdHnvckBw\iCqdX3hckBUVkdvTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|k5PTNizszN MWXTRW5ITVJ?
human MCF7 cell M4fWcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoPLTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64NVc5KM7:TR?= MljWV2FPT0WU
human A431 cell NIfURWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUjRfoJuUW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PTlyMjFOwG0> NGLFeVdUSU6JRWK=
human BC-3 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHVTY5pcWKrdHnvckBw\iCqdX3hckBDSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64O|A6PCEQvF2= MWTTRW5ITVJ?
human A427 cell MoDMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFfzUYhKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg4PjFzIN88US=> Mki0V2FPT0WU
human SW620 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmrzTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVI5OTZizszN NYPESHJZW0GQR1XS
human HOS cell M3HmUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13uT2lvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT65O|MyOiEQvF2= NGr5elRUSU6JRWK=
human MFH-ino cell NGHtRlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\ldIczUW6qaXLpeIlwdiCxZjDoeY1idiCPRlitbY5wKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57OE[1PEDPxE1? NYXrTIlmW0GQR1XS
human TE-12 cell NUWzUHRwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnG1TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuPVkyOjhizszN M3v4[3NCVkeHUh?=
human KU812 cell NEnRUWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHsTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVg4OSEQvF2= NVnCNYJnW0GQR1XS
human NCI-H2342 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7xTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzOFIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjF7MEWzJO69VQ>? MmjqV2FPT0WU
human BC-1 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHXTU5dKdmirYnn0bY9vKG:oIHj1cYFvKEKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlUyPjVzIN88US=> NYfRbYRHW0GQR1XS
human TE-15 cell NFzxXFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXHGWHViUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTlzOEGg{txO Mm\tV2FPT0WU
human T84 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPoXVdKdmirYnn0bY9vKG:oIHj1cYFvKFR6NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlA1PDZizszN MVzTRW5ITVJ?
human SW1710 cell M3zIVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MofBTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlcxODh{IN88US=> M1XofnNCVkeHUh?=
human CAL-12T cell M1nvNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlcyOTV6IN88US=> NYC2bnJnW0GQR1XS
human NKM-1 cell MojSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NY\nR3BZUW6qaXLpeIlwdiCxZjDoeY1idiCQS12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzZ5M{Gg{txO NFLne4hUSU6JRWK=
human OCUB-M cell MoPzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1zvbGlvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44QDh4MTFOwG0> MoTaV2FPT0WU
human 786-0 cell NYrWV|ZQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmOzTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVQ5OjVizszN NFH1UIxUSU6JRWK=
human EW-13 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wNVU2QCEQvF2= Mmf1V2FPT0WU
human 5637 cell NGf0fJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVvJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkKwOlY6KM7:TR?= MWDTRW5ITVJ?
human PA-1 cell M2DpcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkOzNFg{KM7:TR?= M33mPXNCVkeHUh?=
human NCI-H2122 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;kPZRKUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIyOjJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkOzN{DPxE1? NIfu[olUSU6JRWK=
human NCI-H460 cell NEnleHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHhTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDB2MTFOwG0> NI\ZVIlUSU6JRWK=
human CHL-1 cell MlHyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz60PVY3PSEQvF2= Mm\KV2FPT0WU
human MOLT-16 cell NFnJS3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfkTmUyUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53MUW1OUDPxE1? M1rGbHNCVkeHUh?=
human HCT-15 cell MlrKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXnJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlI5PDJizszN MoDEV2FPT0WU
human G-361 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zoOWlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlcyPzR3IN88US=> NIjDbXVUSU6JRWK=
human SK-LU-1 cell NH;pc3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2HNOGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTGWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTdyMUSg{txO MYjTRW5ITVJ?
human ES4 cell NXzVTWg6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoXPTY5pcWKrdHnvckBw\iCqdX3hckBGWzRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkC2NFY6KM7:TR?= MonKV2FPT0WU
human TE-8 cell M2\IcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYj6dmQyUW6qaXLpeIlwdiCxZjDoeY1idiCWRT24JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOTV6MjFOwG0> NFHSc5NUSU6JRWK=
human IGR-1 cell NUGwRppRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\JXmhKdmirYnn0bY9vKG:oIHj1cYFvKEmJUj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zOzNizszN NWjkeJJoW0GQR1XS
human SW954 cell M1fnTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFjzNGZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PjF{NDFOwG0> MV3TRW5ITVJ?
human A375 cell MljkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDwTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yOVQ6OiEQvF2= Mn7OV2FPT0WU
human CAL-27 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7hTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM{OjJzIN88US=> NHHyUFJUSU6JRWK=
human CAL-51 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3HVbWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PTV6MzFOwG0> MV\TRW5ITVJ?
human SK-LMS-1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLFfmpKdmirYnn0bY9vKG:oIHj1cYFvKFONLVzNV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5|OEK1OUDPxE1? MWTTRW5ITVJ?
human HT-1080 cell M1rCT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEm3UppKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR7M{S3JO69VQ>? MWrTRW5ITVJ?
human NCI-H1299 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTh3NUeg{txO MWHTRW5ITVJ?
human HT-29 cell NF7Ob4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2THfWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlI3QDR|IN88US=> M1XJc3NCVkeHUh?=
human A388 cell Mn;MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkW5PVY2KM7:TR?= M2TMenNCVkeHUh?=
human SK-MEL-30 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvQTd{MUWg{txO NFXvb3VUSU6JRWK=
human CMK cell M4H4dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIPv[lZKdmirYnn0bY9vKG:oIHj1cYFvKEOPSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlU{PzdizszN NVjTfmhIW0GQR1XS
human HuP-T4 cell NHTMfHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPlZ3dKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvPTB{M{Sg{txO MlPCV2FPT0WU
human SF126 cell NIfBS5NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD64NFIxQCEQvF2= NInyVJZUSU6JRWK=
human MKN1 cell NXvPe5pCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnxRnpuUW6qaXLpeIlwdiCxZjDoeY1idiCPS16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4yQDV4NTFOwG0> NF\mXXJUSU6JRWK=
human LoVo cell M4\6T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3TJTWlvcGmkaYTpc44hd2ZiaIXtZY4hVG:YbzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPVEzQTJizszN NIfQemFUSU6JRWK=
human HEL cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHET|BKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlY5KM7:TR?= MWLTRW5ITVJ?
human SW872 cell M{Lrfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUnJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuOlg6PiEQvF2= MkfFV2FPT0WU
human SW982 cell NF;WboJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHzvb3FKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvPzlzNjFOwG0> NWXRfYpbW0GQR1XS
human HuH-7 cell Mkf3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX7WW5E{UW6qaXLpeIlwdiCxZjDoeY1idiCKdVitO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE5NjJ5OEOg{txO NU\5NGY4W0GQR1XS
human DU-145 cell Mn;rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1np[mlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvPDl3NTFOwG0> MlnSV2FPT0WU
human MC116 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;JU2lvcGmkaYTpc44hd2ZiaIXtZY4hVUNzMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zPjd4IN88US=> MmjuV2FPT0WU
human H4 cell MlPYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjGN44xUW6qaXLpeIlwdiCxZjDoeY1idiCKNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlQzPDRizszN MV3TRW5ITVJ?
human SK-MEL-3 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLOTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMxNjB{Mkig{txO MX3TRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p21 / LC3 / p62 / PARP / Cleaved PARP ; 

PubMed: 29017179     


PC3 cells were treated as in b; LNCaP cells were treated with DMSO or 80 μm GSK650394 (GSK) for various time points (6, 24 and 48 h). Total protein lysates were collected for western blot against p21, LC3B, p62, PARP and cleaved (CL) PARP; GAPDH was used as a loading control.

c-Jun / NRF2 ; 

PubMed: 31136958     


Western blot analysis of c-JUN and NRF2 proteins in cervical cancer cells treated with or without GSK650394. Vinculin was used as a loading control. 

p-SGK1 / SGK1 ; 

PubMed: 30873046     


Podocytes were exposed to 1, 2.5, 5, 10, or 20 μM GSK650394 for 24 h and then analyzed by immunoblot.

p-SGK2 / SGK2 ; 

PubMed: 26392083     


Western blot analysis of immunoprecipitated p-SGK2 T193 and FLAG-SGK2 from whole cell lysates in pcDNA/FLAG/SGK2-transfected ShP51 cells treated with GSK650394 (10 μM) for 30 and 60 min.

29017179 31136958 30873046 26392083
Immunofluorescence
LC3; 

PubMed: 29017179     


Immunofluorescence staining for LC3 puncta.

29017179
Growth inhibition assay
Cell viability; 

PubMed: 29017179     


Cell viability analysis using a CCK8 assay of prostate cancer cell lines after treatment with various concentrations of GSK650394 or vehicle alone for the indicated time periods. Data are the means of triplicate experiments. The results are expressed as the percentage of viable control cells treated with DMSO alone (vehicle). 

29017179

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Scintillation proximity assay (SPA):

SGK1 S422D (60–431 aa; 0.275 μg/mL final concentration) or SGK2 (0.875 μg/mL final concentration) are activated by PDK1 (1.1 μg/mL final concentration) in a buffer consisting of 50 mM Tris (pH 7.5), 0.1 mM EGTA, 0.1 mM EDTA, 10 mM MgCl2, 0.1% β-mercaptoethanol, 1 mg/mL BSA, and ATP (final concentration of 0.15 mM) and incubated for 30 min at 30°C. SGK2 is prepared exactly as described for SGK1, except it corresponded to the full-length protein. A solution containing biotinylated CROSStide peptide at a final concentration of 75 μM and γ32P-ATP corresponding to 2×106 cpm is prepared in the reaction buffer. In a 96-well plate, 5 μL of GSK650394 is added to 25 μL of the activated enzyme mixture. To this, 20 μL of the CROSStide mixture is added and incubated for 1 h at room temperature. Next, 50 μL of a 25 mg/mL slurry of streptavidin-coated SPA beads in PBS with 0.1 M EDTA, pH 8.0 is added. The plate is then sealed and centrifuged for 8 min at 2000 rpm, and the signal is detected by measuring for 30 sec/well in a Packard TopCount NXT Scintillation Counter. The IC50 values of the inhibition of SGK1 and SGK2 activities by GSK650394 are calculated from these data using GraphPad Prism 3 Software.
細胞試験: [1]
- 合併
  • 細胞株: LNCaP cells
  • 濃度: ~10 μM
  • 反応時間: 7 days
  • 実験の流れ: LNCaP cells are plated at a density of 5,000 cells per well in 96-well plates in 100 μL PRF-RPMI 1640, supplemented with 8% CS-FBS, 0.1 mM NEAA, and 1 mM NaPyr. At day three, cells are treated with hormone with or without GSK650394 by removing 50 μL of the media and replacing this with 50 μL of PRF-RPMI 1640 with 8% CS-FBS, NEAA, NaPyr containing a 2X concentration of the appropriate hormone/inhibitor treatment. At days 5 and 7, the treatment is repeated. On the tenth day, the media is removed and the relative cell number is measured using the FluoReporter Blue assay according to the manufacturer’s instructions.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 76 mg/mL (198.71 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 382.45
化学式

C25H22N2O2

CAS No. 890842-28-1
保管
in solvent
別名 N/A
Smiles OC(=O)C1=C(C=C(C=C1)C2=C[NH]C3=NC=C(C=C23)C4=CC=CC=C4)C5CCCC5

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(余分な消耗を考慮し動物一匹分の量を用意することをお勧めします。)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロットごとに組成が異なるため、セレックから完全に溶解できる組成をお求めください。)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須
Tags: GSK650394を買う | GSK650394 ic50 | GSK650394供給者 | GSK650394を購入する | GSK650394費用 | GSK650394生産者 | オーダーGSK650394 | GSK650394化学構造 | GSK650394分子量 | GSK650394代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID